Trial for Treatment Refractory Trigeminal Neuralgia

PHASE2TerminatedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

May 11, 2023

Study Completion Date

May 11, 2023

Conditions
Trigeminal Neuralgia
Interventions
DRUG

Rimegepant

BHV3000 (rimegepant) 75mg tablet

DRUG

Placebo

Placebo

Trial Locations (20)

11042

Neurological Surgery Practice of Long Island PLCC, Lake Success

Neurological Surgery, Lake Success

Premier Cardiolog Consultants, Lake Success

Premier Cardiolog Consultants, New Hyde Park

Premier Cardiology Consultants, New Hyde Park

11776

North Suffolk Neurology, PC, Port Jefferson Station

14226

Dent Neurosciences Research Center, Amherst

21287

Johns Hopkins Clinical Outpatient Center, Baltimore

Johns Hopkins ICTR Clinical Research Unit (CRU), Baltimore

33136

SouthCoast Research Center, Miami

45459

Neurology Diagnostics Inc., Dayton

63005

Clinical Research Professionals, Chesterfield

70115

Ochsner Baptist Medical Center, New Orleans

85297

Gilbert Neurology Partners, PLLC/CCT Research, Gilbert

92037

Center for Neurohealth DBA Kaizen Brain Center, La Jolla

94304

Imaging Clinic at Stanford Neuroscience Health Center, Palo Alto

Stanford Hoover Pavilion, Palo Alto

Stanford Neuroscience Health Center- SNHC Pharmacy, Palo Alto

Stanford Neuroscience Health Center, Palo Alto

94305

Stanford University- CAM Building, Stanford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY